Drug Patents owned by Cmp Dev Llc

1. Drug name - CAROSPIR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10493083 CMP DEV LLC Spironolactone aqueous compositions Oct, 2036

(14 years from now)

US10660907 CMP DEV LLC Spironolactone aqueous compositions Oct, 2036

(14 years from now)

US10624906 CMP DEV LLC Spironolactone aqueous compositions Oct, 2036

(14 years from now)

US9757394 CMP DEV LLC Spironolactone aqueous formulations Oct, 2036

(14 years from now)

US10888570 CMP DEV LLC Spironolactone aqueous compositions Oct, 2036

(14 years from now)

Drugs and Companies using SPIRONOLACTONE ingredient

Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/5ML SUSPENSION;ORAL Prescription

2. Drug name - NORLIQVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253474 CMP DEV LLC Pharmaceutical solution of amlodipine Feb, 2041

(18 years from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; norliqva is indicated for the symptomatic treatment of chronic stable angina; norliqva is indicated for the treatment of confirmed or suspected vasospastic angina

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/ML SOLUTION;ORAL Prescription

3. Drug name - POTASSIUM PHOSPHATES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632150 CMP DEV LLC Potassium phosphates composition for injection Apr, 2039

(16 years from now)

Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient

Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.